Q-omics provides the consensus-scored GALNT8 profile across patient tissues and cancer cell-line models. GALNT8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, GALNT8 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, GALNT8 RNA expression shows 13,551 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, BRCA, and TGCT as cancer lineages where GALNT8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT8 survival associations across molecular data types. GALNT8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT8 RNA expression–survival associations across cancer types. High GALNT8 expression shows unfavorable associations in BLCA, ESCA and OV, but favorable associations in SKCM, PAAD and CHOL. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SKCM as the clearest survival context for GALNT8 RNA expression.
This table summarizes GALNT8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GALNT8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT8 shows lower tumor expression in BRCA, UCEC, THCA, KIRP, KICH and COAD. The BRCA box plot shows higher GALNT8 RNA expression in normal versus tumor tissue (log2 FC = −0.636, t-test p < 0.001).
This table shows molecular features associated with GALNT8 in patient tissues and cancer cell lines. In patient samples, GALNT8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
